Securities Litigation + Enforcement Highlights From Q4 2023

Closing out 2023, Cooley's securities litigation + enforcement practice continued providing guidance to our clients on recent developments in securities law – with a particular focus during the fourth quarter on Securities and Exchange Commission (SEC) enforcement trends. Below is a roundup of key insights and developments from our team for Q4 2023.

Highlights

Parallel SEC, FDA Regulatory Enforcement: What Life Sciences Companies Should Know

While parallel enforcement by the SEC and the Food and Drug Administration (FDA) is not new, it appears to be gaining favor among regulators. Life sciences companies should be aware of this phenomenon and the interplay between the SEC and FDA regulatory regimes. Key takeaways include staying vigilant about compliance, understanding what's important to each set of regulators (and the potential exposure presented by various statutes), and anticipating enforcement strategies and the timing of parallel investigations.